Mini Review

You have full text access to this OnlineOpen article

Cervical cancer control, priorities and new directions

  1. Joseph Monsonego1,†,*,
  2. F. Xavier Bosch2,
  3. Pierre Coursaget3,
  4. John Thomas Cox4,
  5. Eduardo Franco5,
  6. Ian Frazer6,
  7. Rengaswamy Sankaranarayanan7,
  8. John Schiller8,
  9. Albert Singer9,
  10. Tom Wright10,
  11. Walter Kinney11,
  12. Chris Meijer12,
  13. James Linder13

Article first published online: 24 OCT 2003

DOI: 10.1002/ijc.11530

Issue

International Journal of Cancer

International Journal of Cancer

Volume 108, Issue 3, pages 329–333, 20 January 2004

Additional Information

How to Cite

Monsonego, J., Bosch, F. X., Coursaget, P., Cox, J. T., Franco, E., Frazer, I., Sankaranarayanan, R., Schiller, J., Singer, A., Wright, T., Kinney, W., Meijer, C. and Linder, J. (2004), Cervical cancer control, priorities and new directions. Int. J. Cancer, 108: 329–333. doi: 10.1002/ijc.11530

Author Information

  1. 1

    EUROGIN, Paris, France

  2. 2

    Epidemiology and Cancer Registration Unit, Catalan Institute of Oncology, Barcelona, Spain

  3. 3

    Faculté de Pharmacie, Lab. d'Immunologie des Maladies Infectieuses, Tours, France

  4. 4

    Health Services, University of California, Santa Barbara, CA, USA

  5. 5

    Department of Oncology, Mc Gill University, Montreal, Canada

  6. 6

    CICR, Princess Alexandra Hospital, Woolloongabba Queensland, Australia

  7. 7

    IARC-International Agency for Research on Cancer, Lyon Cedex, France

  8. 8

    Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, MD, USA

  9. 9

    Dept. of Obstetrics and Gynaecology, Whittington and Royal Northern Hospital, London, UK

  10. 10

    College of Physicians and Surgeons, Columbia Universit, New York, NY, USA

  11. 11

    Sacramento Gynecologic Oncology, The Permanente Medical Group, Inc., Sacramento, CA, USA

  12. 12

    Academisch Ziekenhuis, Vrije Universiteit, Amsterdam, The Netherlands

  13. 13

    Cytyc Corporation, Boxborough, MA, USA

  1. †

    Fax: +33-1-47-66-74-70

*EUROGIN, 174 rue de Courcelles, 75017 Paris, France

Publication History

  1. Issue published online: 21 NOV 2003
  2. Article first published online: 24 OCT 2003
  3. Manuscript Accepted: 1 AUG 2003
  4. Manuscript Received: 28 JUL 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (75K)

REFERENCES

  • 1
    Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, Kantelip B, Schaal JP, Mougin C. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003; 106: 396–403.
    Direct Link:
  • 2
    Franco EL, Villa LL, Sobrinho JP, Prado JM, Rousseau M, Désy M, Rohan TE. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999; 180: 1415–23.
  • 3
    Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92: 464–74.
  • 4
    Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518–27.
  • 5
    Bosch FX, Lorincz A, Munoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244–65.
  • 6
    Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S; International Agency for Research on Cancer. Milticentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359: 1085–92.
  • 7
    Acladious NN, Sutton C, Mandal D, Hopkins R, Zaklama M, Kitchener H. Persistent human papillomavirus infection and smoking increase risk of failure of treatment of cervical intraepithelial neoplasia (CIN). Int J Cancer 2002; 98: 435–9.
    Direct Link:
  • 8
    Castellsagué X, Bosch FX, Muñoz N, Meijer CJLM, Shah KV, de Sanjose S, Eluf-Neto J, Ngelangel CA, Chichareon S, Smith JS, Herrero R, Moreno V, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346: 1105–12.
  • 9
    Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995; 141: 680–9.
  • 10
    Saslow D, Runowicz CD, Solomon D, Moscicki A-B, Smith RA, Eyre HJ, Cohen C. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342–62.
    Direct Link:
  • 11
    Limaye A, Connor AJ, Huang X, Luff R. Comparative analysis of conventional Papanicolaou tests and a fluid-based thin-layer method. Arch Pathol Lab Med 2003; 127: 200–4.
  • 12
    Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis sample adequacy. Am J Obstet Gynecol 2001; 185: 308–17.
  • 13
    Monsonego J, Autillo-Touati A, Bergeron C, Dachez R, Liaras J, Saurel J, Zerat L, Mottot P. Liquid based cytology for primary cervical cancer screening: a multicentre study. Br J Cancer 2001; 84: 382–6.
  • 14
    National Institute for Clinical Excellence. Report on liquid based cytology. www.nice.org.uk
  • 15
    Agency for Health Care Policy and Research. Evidence report/technology assessment no. 5, evaluation of cervical cytology. February 1999. AHCRP Publication No. 99-E010. Rockville, MD: US Department of Health and Human Services.
  • 16
    Nobbenhuis M, Walboomers JM, Helmerhorst T, Rozendaal L. Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999; 354: 20.
  • 17
    Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 46–52.
  • 18
    Petry K-U, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8468 patients. Br J Cancer 2003; 88: 1570–7.
  • 19
    Clavel C, Masure M, Bory J-P, Putaud I, Mangeonjean C, Lorenzato F, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001; 89: 1616–23.
  • 20
    Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, Alfaro M, Hutchinson M, Morales J, Greenberg MD, Lorincz AT. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000; 5: 87–93.
  • 21
    University of Zimbabwe/JHPIEGO Cervical Cancer Project. Visual inspection with acetic acid for cervical cancer screening: test qualities in a primary-care setting. Lancet 1999; 353: 869–73.
  • 22
    Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, Pan QJ, Fischer C, Lorincz A, Zahniser D. Shanxi province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001; 83: 439–444.
  • 23
    Sankaranarayanan R, Wesley R, Thara S, Dhakad N, Chandralekha B, Sebastian P, Chithrathara K, Parkin DM, Nair MK. Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol's iodine (VILI) in cervical cancer screening in Kerala, India. Int J Cancer 2003; 106: 404–8.
    Direct Link:
  • 24
    Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001; 285: 3107–15.
  • 25
    Sasieni P, Cuzick J. Could HPV testing become the sole primary cervical screening test? J Med Screen 2002; 9: 49–51.
  • 26
    Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 ASCCP-sponsored Consensus Workshop. Consensus guidelines for the management of women with cervical cytological abnormalities and cervical cancer precursors–part I: cytological abnormalities. JAMA 2002; 287: 2120–9.
  • 27
    Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998; 91: 626–31.
  • 28
    Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999; 281: 1605–10.
  • 29
    Solomon D, Schiffman M, Tarone R; ALTS Study group. Comparison of HPV testing, repeat cytology, and immediate colposcopy in ASCUS triage: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93: 293–9.
  • 30
    Guido R, Schiffman M, Solomon D, Burke L; ASCUS LSIL Triage Study (ALTS) Group. Post-colposcopy management strategies for women referred for low-grade squamous intraepithelial lesions or human papillomavirus DNA-positive atypical squamous cells of undetermined significance: a two-year prospective study. Am J Obstet Gynecol 2003; 188: 1401–5.
  • 31
    zur Hausen H. Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 2001; 93: 252–3.
  • 32
    Steller MA. Cervical cancer vaccines: progress and prospects. J Soc Gynecol Investig 2002; 9: 254–64.
  • 33
    Schiller J, Lowy D. Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2001; (28): 50–4.
  • 34
    Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC. A Phase 1 study of a recombinant virus like particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183: 1485–93.
  • 35
    Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93: 284–92.
  • 36
    Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645–51.
  • 37
    Stewart TJ, Smyth MJ, Fernando GJ, Frazer IH, Leggatt GR. Inhibition of early tumor growth requires J α18-positive (natural killer T) cells. Cancer Res 2003; 63: 3058–60.
  • 38
    Leachman SA, Shylankevich M, Slade MD, Levine D, Sundaram RK, Xiao W, Bryan M, Zelterman D, Tiegelaar RE, Brandsma JL. Ubiquitin-fused and/or multiple papillomavirus early genes from cottontail rabbit as DNA vaccines. J Virol 2002; 76: 7616–24.
  • 39
    Stanley MA. Human papillomavirus vaccines. Curr Opin Mol Ther 2002; 4: 15–22.
View Full Article (HTML) Get PDF (75K)